These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24218258)

  • 1. Purification and functional analysis of human properdin.
    O'Flynn J; Krol MC; Daha MR; van Kooten C
    Methods Mol Biol; 2014; 1100():161-7. PubMed ID: 24218258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fractionation of human plasma proteins. I. Affinity purification of human complement properdin.
    DiScipio RG
    Protein Expr Purif; 1994 Apr; 5(2):164-9. PubMed ID: 8054850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rabbit properdin system: I. Identification of a new factor and purification of rabbit properdin.
    Naff GB; Hedrick SW; Ratnoff WD; Novak MA; Smith MC; Steiner C; Todd EW
    J Immunol; 1980 Jun; 124(6):2625-31. PubMed ID: 6900053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation.
    Xu W; Berger SP; Trouw LA; de Boer HC; Schlagwein N; Mutsaers C; Daha MR; van Kooten C
    J Immunol; 2008 Jun; 180(11):7613-21. PubMed ID: 18490764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution and analysis of 'native' and 'activated' properdin.
    Farries TC; Finch JT; Lachmann PJ; Harrison RA
    Biochem J; 1987 Apr; 243(2):507-17. PubMed ID: 3307764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properdin Pattern Recognition on Proximal Tubular Cells Is Heparan Sulfate/Syndecan-1 but Not C3b Dependent and Can Be Blocked by Tick Protein Salp20.
    Lammerts RGM; Talsma DT; Dam WA; Daha MR; Seelen MAJ; Berger SP; van den Born J
    Front Immunol; 2020; 11():1643. PubMed ID: 32849563
    [No Abstract]   [Full Text] [Related]  

  • 8. The Role of Properdin in Killing of Non-Pathogenic
    Martinez APG; Abreu PAE; de Arruda Vasconcellos S; Ho PL; Ferreira VP; Saggu G; Barbosa AS; Isaac L
    Front Immunol; 2020; 11():572562. PubMed ID: 33240263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
    Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
    Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and characterisation of the thrombospondin type I repeats of human properdin.
    Perdikoulis MV; Kishore U; Reid KB
    Biochim Biophys Acta; 2001 Aug; 1548(2):265-77. PubMed ID: 11513971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement.
    Smith CA; Pangburn MK; Vogel CW; Müller-Eberhard HJ
    J Biol Chem; 1984 Apr; 259(7):4582-8. PubMed ID: 6707020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covalent linkage of C3 to properdin during complement activation.
    Whiteman LY; Purkall DB; Ruddy S
    Eur J Immunol; 1995 May; 25(5):1481-4. PubMed ID: 7774654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation by tubular cells is mediated by properdin binding.
    Gaarkeuken H; Siezenga MA; Zuidwijk K; van Kooten C; Rabelink TJ; Daha MR; Berger SP
    Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1397-403. PubMed ID: 18753294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Native and activated properdin: interconvertibility and identity of amino- and carboxy-terminal sequences.
    Medicus RG; Esser AF; Fernandez HN; Müller-Eberhard HJ
    J Immunol; 1980 Feb; 124(2):602-6. PubMed ID: 6766162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the natural polymeric forms of human properdin and their functions in complement activation.
    Pangburn MK
    J Immunol; 1989 Jan; 142(1):202-7. PubMed ID: 2909614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan.
    Wilson JG; Fearon DT; Stevens RL; Seno N; Austen KF
    J Immunol; 1984 Jun; 132(6):3058-63. PubMed ID: 6427331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin.
    Götze O; Medicus RG; Müller-Eberhard HJ
    J Immunol; 1977 Feb; 118(2):525-32. PubMed ID: 839069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.
    Ferreira VP; Cortes C; Pangburn MK
    Immunobiology; 2010 Nov; 215(11):932-40. PubMed ID: 20382442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.